YSK05 | CAS#1318793-78-0 | Ionizable amino lipid

MedKoo Cat#: 465262 | Name: YSK05

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YSK05 is an ionizable amino lipid (apparent pKa = ~6.5) that has been used in combination with other lipids in the formation of liposomes and lipid nanoparticles (LNPs). Administration of cyclic di-GMP (Item No. 17144) in YSK05-containing liposomes increases serum levels of IFN-β, IFN-γ, IL-6, and TNF-α and activates natural killer (NK) cells in mice, as well as decreases lung metastasis in a B16/F10 murine melanoma model of metastasis. Intravenous administration of factor VII siRNA in YSK05-containing LNPs reduces factor VII activity in isolated mouse plasma.

Chemical Structure

YSK05

CAS# 1318793-78-0

Theoretical Analysis

MedKoo Cat#: 465262

Name: YSK05

CAS#: 1318793-78-0

Chemical Formula: C42H77NO2

Exact Mass: 627.5954

Molecular Weight: 628.08

Elemental Analysis: C, 80.32; H, 12.36; N, 2.23; O, 5.09

Price and Availability

Size	Price	Availability
5mg	USD 295.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

YSK05; YSK 05; YSK-05;

IUPAC/Chemical Name

1-methyl-4,4-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)piperidine

InChi Key

KURBRAZBXURPCJ-QYCRHRGJSA-N

InChi Code

InChI=1S/C42H77NO2/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-40-44-42(36-38-43(3)39-37-42)45-41-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2/h12-15,18-21H,4-11,16-17,22-41H2,1-3H3/b14-12-,15-13-,20-18-,21-19-

SMILES Code

CCCCC/C=C\C/C=C\CCCCCCCCOC1(OCCCCCCCC/C=C\C/C=C\CCCCC)CCN(C)CC1

Appearance

A solution in ethanol

Purity

>90% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C22M09C07

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Ethanol	25.0	39.80

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 628.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hagino Y, Khalil IA, Kimura S, Kusumoto K, Harashima H. GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs. Mol Pharm. 2021 Mar 1;18(3):878-888. doi: 10.1021/acs.molpharmaceut.0c00854. Epub 2021 Jan 25. PMID: 33492961. 2: Sakurai Y. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device]. Yakugaku Zasshi. 2019;139(11):1357-1363. Japanese. doi: 10.1248/yakushi.19-00150. PMID: 31685731. 3: Kimura S, Khalil IA, Elewa YHA, Harashima H. Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization. J Control Release. 2019 Nov 10;313:70-79. doi: 10.1016/j.jconrel.2019.09.009. Epub 2019 Sep 14. PMID: 31526828. 4: Younis MA, Khalil IA, Abd Elwakil MM, Harashima H. A Multifunctional Lipid- Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Mol Pharm. 2019 Sep 3;16(9):4031-4044. doi: 10.1021/acs.molpharmaceut.9b00738. Epub 2019 Aug 23. PMID: 31403802. 5: Shobaki N, Sato Y, Harashima H. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting. Int J Nanomedicine. 2018 Dec 10;13:8395-8410. doi: 10.2147/IJN.S188016. PMID: 30587967; PMCID: PMC6294068. 6: Sato Y, Matsui H, Sato R, Harashima H. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA. J Control Release. 2018 Aug 28;284:179-187. doi: 10.1016/j.jconrel.2018.06.017. Epub 2018 Jun 21. PMID: 29936118. 7: Khalil IA, Kimura S, Sato Y, Harashima H. Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles. J Control Release. 2018 Apr 10;275:107-116. doi: 10.1016/j.jconrel.2018.02.016. Epub 2018 Feb 13. PMID: 29452131. 8: Yamamoto S, Kato A, Sakurai Y, Hada T, Harashima H. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release. 2017 Apr 10;251:1-10. doi: 10.1016/j.jconrel.2017.02.010. Epub 2017 Feb 10. PMID: 28192155. 9: Sato Y, Harashima H, Kohara M. A Multifunctional Envelope-Type Nano Device Containing a pH-Sensitive Cationic Lipid for Efficient Delivery of Short Interfering RNA to Hepatocytes In Vivo. Methods Mol Biol. 2016;1364:71-8. doi: 10.1007/978-1-4939-3112-5_7. PMID: 26472443. 10: Matsui H, Sato Y, Hatakeyama H, Akita H, Harashima H. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. Int J Pharm. 2015 Nov 10;495(1):171-178. doi: 10.1016/j.ijpharm.2015.08.044. Epub 2015 Sep 7. PMID: 26355712. 11: Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release. 2015 Oct 28;216:149-57. doi: 10.1016/j.jconrel.2015.08.026. Epub 2015 Aug 14. PMID: 26282097. 12: Sakurai Y, Matsuda T, Hada T, Harashima H. Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes. Biol Pharm Bull. 2015;38(8):1185-91. doi: 10.1248/bpb.b15-00138. PMID: 26235581. 13: Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm. 2014 Aug 4;11(8):2713-9. doi: 10.1021/mp500245z. Epub 2014 May 12. PMID: 24800640. 14: Hyodo M, Sakurai Y, Akita H, Harashima H. "Programmed packaging" for gene delivery. J Control Release. 2014 Nov 10;193:316-23. doi: 10.1016/j.jconrel.2014.04.023. Epub 2014 Apr 26. PMID: 24780263. 15: Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy. J Control Release. 2014 Jun 28;184:20-7. doi: 10.1016/j.jconrel.2014.04.004. Epub 2014 Apr 13. PMID: 24727060. 16: Tamaru M, Akita H, Kajimoto K, Sato Y, Hatakeyama H, Harashima H. An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. Int J Pharm. 2014 Apr 25;465(1-2):77-82. doi: 10.1016/j.ijpharm.2014.02.016. Epub 2014 Feb 12. PMID: 24530390. 17: Hatakeyama H, Murata M, Sato Y, Takahashi M, Minakawa N, Matsuda A, Harashima H. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J Control Release. 2014 Jan 10;173:43-50. PMID: 24511611. 18: Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J Control Release. 2014 Jan 10;173:110-8. doi: 10.1016/j.jconrel.2013.10.003. Epub 2013 Oct 11. PMID: 24120854. 19: Takahashi M, Yamada N, Hatakeyama H, Murata M, Sato Y, Minakawa N, Harashima H, Matsuda A. In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Res. 2013 Dec;41(22):10659-67. doi: 10.1093/nar/gkt823. Epub 2013 Sep 11. PMID: 24030710; PMCID: PMC3905841. 20: Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther. 2013 Jun;21(6):1195-203. doi: 10.1038/mt.2013.57. Epub 2013 Apr 9. PMID: 23568259; PMCID: PMC3677313.